Compare MGM Resorts International (MGM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Neurocrine Biosciences Inc — how do they compare? MGM Resorts International trades at $46.57 (market cap $11.86B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MGM | NBIX | |
|---|---|---|
Market Cap | $11.86B | $17.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $180.55 |
52-Week Low | $30.72 | $123.10 |
Enterprise Value | $40.90B | $16.49B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM trades at $45.67, down 1.0% today, with a neutral technical stance and mixed earnings history. The company reported $17.54B revenue in 2025 but net income fell to $206M, with profit margins narrowing. Recent news highlights acquisition interest from Barry Diller at $48.30 per share, creating investor uncertainty. Cash flow trends show improving operational strength, though net cash flow remains negative.
Outlook is balanced: potential upside exists from the acquisition offer and steady revenue, but risks include declining profitability and high debt. Analysts are split evenly between Buy and Hold, with a $48.93 consensus target suggesting modest upside. Investors should weigh takeover prospects against fundamental pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
